Previous 10 | Next 10 |
2024-02-28 22:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-18 05:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-16 12:30:02 ET Goldman Sachs analyst issues NEUTRAL recommendation for ALNY on February 16, 2024 12:00PM ET. ALNY was trading at $147.8925 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 8 - Buy, ...
A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 66.7% to $3.76 on volume of 298,289,429 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 70.5% to $0.1091 on volume of 172,174,410 shares Sientra Inc. (SIEN) rose 89.9% to $0.342 on volume of ...
A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 62.5% to $3.665 on volume of 269,509,234 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 64.1% to $0.105 on volume of 159,463,786 shares Sientra Inc. (SIEN) rose 119.4% to $0.395 on volume of...
2024-02-15 13:16:06 ET Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2023 Earnings Conference Call February 15, 2024 08:30 ET Company Participants Christine Lindenboom - Senior Vice President, Investor Relations and Corporate Communications Yvonne Greenstreet - Chief Execu...
2024-02-15 12:39:02 ET Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) were sinking 9.5% lower as of 11:27 a.m. ET on Thursday after falling as much as 12.6% earlier in the day. The sell-off came after the drugmaker announced its fourth-quarter and full-year 2023 results. Alnyl...
2024-02-15 09:12:07 ET More on Alnylam Pharmaceuticals Alnylam's Huge Opportunity Alnylam Pharmaceuticals: R&D Day Reveals Ambitious Plans Alnylam Pharmaceuticals Q4 2023 Earnings Preview Investors growing more bullish on SMID cap biotech stocks S...
2024-02-15 08:04:42 ET More on Alnylam Pharmaceuticals Alnylam's Huge Opportunity Alnylam Pharmaceuticals: R&D Day Reveals Ambitious Plans Alnylam Pharmaceuticals Q4 2023 Earnings Preview Investors growing more bullish on SMID cap biotech stocks S...
− Achieved Fourth Quarter and Full Year 2023 Global Net Product Revenues of $346 Million and $1,241 Million, Respectively, Representing 39% Annual Growth Compared to 2022 – − Company Announces Updated Statistical Analysis Plan and Timing for HELIOS-B Phase 3 Study of ...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
− Achieved First Quarter 2024 Global Net Product Revenues of $365 Million, Representing 32% Year-Over-Year Growth Compared to Q1 2023, Including Continued Momentum from Total TTR Delivering 29% Year-Over-Year Growth – − Demonstrated Strong Progress with Zilebesiran Hy...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...